Fate Therapeutics (FATE) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Fate Therapeutics (FATE) overview

Fate Therapeutics (FATE) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 6.6m and operating profit of USD -148m; the year-end share price was 0.98 USD and market capitalisation was USD 113m. Fate Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Fate Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 207mFY 2025
Share price0.98 USDFY 2025 year end
RevenueUSD 6.6mFY 2025
Operating profitUSD -148mFY 2025
Net earningsUSD -136mFY 2025
Market capitalisationUSD 113mFY 2025 year end

About Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies for cancer and autoimmune diseases. Using a proprietary induced pluripotent stem cell platform, it engineers clonal master cell lines and differentiates them into uniform T-cell and natural killer cell candidates. Its pipeline includes chimeric antigen receptor-targeted therapies designed for potential use alone or alongside standard treatments.

Generate the Fate Therapeutics report

Fate Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Fate Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Fate Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.